Newsletter
Lupin is collaborating with TB Alliance to advance the development and commercialisation of Telacebec (Q203), an investigational drug for tuberculosis, leprosy, and buruli ulcer.
TB Alliance is a non-profit drug developer focused on fighting infectious diseases, while Lupin is a global pharma major with deep strength in manufacturing and global supply chains.
The deets: under the agreement, TB Alliance will continue to lead the clinical development of Telacebec. Lupin will step in on manufacturing, regulatory approvals, and global distribution, helping scale the drug once it’s ready for the market.
Why it’s important: Tuberculosis remains one of the world’s deadliest infectious diseases. According to the World Health Organization, around 10.6 million people fell ill with TB globally in 2023, and nearly 1.3 million people died from the disease.
Current treatments are long, toxic, and expensive, often requiring 6–18 months of therapy, which leads to poor patient compliance and higher failure rates.
This is where Telacebec (Q203) matters. It targets TB in a new way, offering the potential for shorter, more effective treatment regimens, especially for drug-resistant strains. If successful, it could reduce treatment duration, improve cure rates, and cut transmission.
Despite years of progress, TB remains stubbornly high in parts of Asia, with India with nearly 195 cases per 100,000 and Indonesia still carrying a heavy disease burden, far above regional peers.
